Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital
March 11, 2025 08:00 ET
|
Alzamend Neuro, Inc.
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial for AL001 Treatment of Post-Traumatic Stress Disorder at Massachusetts General Hospital
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital
March 04, 2025 08:10 ET
|
Alzamend Neuro, Inc.
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder at Massachusetts General Hospital
Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital
February 25, 2025 08:00 ET
|
Alzamend Neuro, Inc.
Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital
New Immunomodulatory Therapeutic Vaccine that Targets Oligomeric Amyloid-β Could be Step Towards Halting Alzheimer’s Disease Progression
October 27, 2020 06:56 ET
|
Alzamend Neuro, Inc.
TAMPA, Fla., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Alzheimer’s disease affects more than 5.8 million Americans at an estimated cost at over $305 billion in 2020 according to the Alzheimer's Association....
Alzamend Neuro™ Completes New Management Team for 2019
December 26, 2018 09:00 ET
|
Alzamend Neuro, Inc.
Tampa, Fla., Dec. 26, 2018 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has appointed top-tier financial executive, Kenneth S. Cragun, CPA, as its...
Alzamend Neuro™ Appoints New CEO, Bio-Pharma Executive Stephan Jackman
November 20, 2018 09:00 ET
|
Alzamend Neuro, Inc.
Salt Lake City, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has appointed bio-pharma executive, Mr. Stephan Jackman, as its new Chief...
Alzamend Neuro™ Secures New Licenses from USF to Treat Alzheimer’s Disease
October 29, 2018 09:00 ET
|
Alzamend Neuro, Inc.
Salt Lake City, UT, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it secured two new licenses from the University of South Florida (“USF”)...
Alzamend Neuro™ Launches Pursuit to Secure FDA IND and First Stage Clinicals
October 24, 2017 22:35 ET
|
Alzamend Neuro, Inc.
SALT LAKE CITY, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has selected TAMM Net of Marietta, GA to lead its FDA regulatory...
USF Researcher Develops Therapeutic Vaccine to Combat Alzheimer’s Disease and Neurodegenerative Disorders
January 30, 2017 06:00 ET
|
Alzamend Neuro, Inc.
SALT LAKE CITY, Jan. 30, 2017 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) reprints by permission of the University of South Florida (USF) Technology Transfer Office this...
Alzamend Neuro™ Announces TV Icon Willie Aames as International Spokesperson
January 09, 2017 06:00 ET
|
Alzamend Neuro, Inc.
SALT LAKE CITY, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today Willie Aames will serve as its International Spokesperson while joining the team...